Preferred Label : IDO-1 Inhibitor LY3381916;
NCIt synonyms : IDO1 Inhibitor LY3381916;
NCIt related terms : LY-3381916;
NCIt definition : An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with
potential immunomodulating and antineoplastic activities. Upon administration, IDO1
inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible
for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite
kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916
restores and promotes the proliferation and activation of various immune cells, including
dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a
reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune
system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL)
response against the IDO1-expressing tumor cells, thereby inhibiting the growth of
IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays
an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte
proliferation and activation, and subsequently suppresses the immune system.;
UNII : 10T9596ILQ;
CAS number : 2166616-75-5;
Molecule name : LY-3381916;
NCI Metathesaurus CUI : CL541448;
Origin ID : C143068;
UMLS CUI : C4684957;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
